'Bionanotechnology from Theory to Practice' is a short online, course providing an interdisciplinary and up-to-date overview of the rapidly developing area of bionanotechnology
Page URL: https://www.bionews.org.uk/page_93657

Huntington's disease gene-silencing drug effective in animal studies

25 June 2012
Appeared in BioNews 662

A single dose of an 'antisense' drug has been shown to slow, or even partially reverse, Huntington's disease in animal studies, according to a study published in Neuron.

Huntington's disease is caused by a mutation of the huntingtin gene, which produces fragments of toxic protein that build up in the brain. The build-up eventually leads to characteristic uncontrolled movements, as well as cognitive and psychiatric problems. There is currently no effective treatment available.

The potential new therapy is based on single strands of DNA called 'antisense oligonucleotides' (ASOs). The ASOs selectively attach themselves to messenger molecules sent by the defective gene and destroy them, blocking the signal that produces the mutant protein.

In tests, mice showed significant improvements in both behavioural and physical symptoms after an injection of ASOs, even in those with an advanced form of the disease. After one month of treatment, the mice showed a significant improvement in motor function, and after two months they were approaching normal levels of movement.

The improvements persisted for up to nine months after treatment, even after levels of the toxic protein fragments had built up again. In severe cases of the disease, the ASOs appeared to prolong lifespan and dramatically slow brain cell death.

The study was carried out at the Ludwig Institute for Cancer Research and Department of Cellular and Molecular Medicine at the University of California, in collaboration with Genzyme, Isis Pharmaceuticals and the Novartis Institutes for BioMedical Research.

Symptoms of Huntington's disease usually begin to appear between the ages of 30 and 50 in people with the defective gene, but the mutant protein can build up for years before manifesting itself. A genetic test can detect the presence of the mutation long before the disease takes hold, and so the possibility of slowing the production of the protein before it causes real damage could one day become a reality.

'Our approach is feasible for development now into a therapy for Huntington's disease in man', said lead author Professor Don Cleveland, from the University of California at San Diego. 'For diseases like Huntington's, where a mutant protein product is tolerated for decades prior to disease onset, these findings open up the provocative possibility that transient treatment can lead to a prolonged benefit to patients'.

Most potential treatments have looked into alleviating the symptoms of Huntington's disease rather than reversing the damage, as multiple areas of the brain are affected, making them difficult to target.

Professor Cleveland said that the ASO approach is especially promising because antisense therapies have already been approved in clinical trials, and researchers are looking into other potential applications. He said the findings may have implications for other 'age-dependent neurodegenerative diseases that develop from exposure to a mutant protein product' and perhaps for nervous system cancers, such as glioblastomas.

Antisense Oligos Reverse Huntington Disease Phenotype in Mice
Genetic Engineering and Biotechnology News |  21 June 2012
Drug 'could reset disease clock'
Press Association |  21 June 2012
Huntingdon's disease cure a step closer after scientists reverse disorder in mice
Mail Online |  20 June 2012
Long-sought treatment for Huntington's disease a step closer to reality
EurekAlert! |  20 June 2012
Proposed drug may reverse Huntington's disease symptoms
EurekAlert! |  20 June 2012
Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis
Neuron |  21 June 2012
19 February 2018 - by Hannah Somers 
Researchers have discovered that the protein responsible for the development of Huntington's disease is highly toxic to cancer cells...
26 June 2017 - by Dr Meghna Kataria 
Eliminating the faulty protein that causes Huntingdon's disease goes some way to reversing disease progression in mice, a study has found...
12 June 2017 - by Dr Lea Goetz 
Scientists have identified the first promising biomarker for Huntington's disease (HD) that could be harnessed in a simple blood test to predict disease onset and progression...
3 August 2015 - by Dr Victoria Burchell 
A genome-wide study of over 4000 people with Huntington's disease has identified the location several new gene variants that influence the onset of disease symptoms...
13 July 2015 - by Dr Julia Hill 
Julia Hill reviews 'The Lion's Mouth Opens', a moving portrait of Huntington's Disease...
23 January 2012 - by Dr Zara Mahmoud 
Two independent studies have suggested new targets for treating neurodegenerative diseases...
5 July 2010 - by Dr Jay Stone 
Two papers published in the Lancet have suggested that the number of people in the UK suffering with Huntington’s disease (HD) may be double original figures and that patients are failing to be diagnosed due to the stigma attached to the illness...
7 September 2009 - by Ailsa Stevens 
Clinicians should be cautious about offering genetic testing to patients at risk from Huntington's disease to enable them to participate in clinical trials, Dr Sheila Simpson, a Clinical Geneticist at NHS Grampian Hospital, said in a talk at the annual conference of the British Society of Human Genetics at Warwick University....
2 August 2009 - by Rosie Beauchamp 
A paper published in the 'Proceedings of the National Academy of Sciences' has outlined disappointing conclusions surrounding the use of brain tissue transplants to treat Huntington's disease. Thomas Freedman and colleagues at the University of South Florida in Tampa, US, report that transplanting portions of fetal brain tissue is not as successful as was previously believed....
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.